Precision BioSciences Inc (DTIL) FinancialsDTILPrecision BioSciences Inc

Precision Biosciences, Inc (DTIL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Therapeutics, accounting for 84.6% of total sales, equivalent to $5.36M. Another important revenue stream is Food. Understanding this composition is critical for investors evaluating how DTIL navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Precision Biosciences, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -112.69%, provide a clear picture of how effectively DTIL converts its operational activities into shareholder value.

In the context of the broader market, DTIL competes directly with industry leaders such as CRDL and RNAC. With a market capitalization of $226.87M, it holds a leading position in the sector. When comparing efficiency, DTIL's gross margin of N/A stands against CRDL's N/A and RNAC's 100.00%. Such benchmarking helps identify whether Precision Biosciences, Inc is trading at a premium or discount relative to its financial performance.

The company has a gross margin of 100% across recent quarters, reflecting strong revenue potential despite current losses. The latest revenue report shows a significant increase to $10.84 million, exceeding expectations by $6.79 million, indicating potential for future growth.